1 A confounder debiasing method for RCT-like comparability enables Machine Learning-2 based personalization of survival benefit in living donor liver transplantation

3

Anirudh Gangadhar*^[a,b], Bima J. Hasjim*^[c], Xun Zhao^[d], Yingji Sun^[b], Joseph Chon^[a], Aman
Sidhu^[a], Elmar Jaeckel^[a,f], Nazia Selzner^[a,f], Mark S. Cattral^[a,e], Blayne A. Sayed^[a], Michael
Brudno^[g-i], Chris McIntosh^{‡[b,g,h,j-i]}, Mamatha Bhat^{‡[a,b,f,h]}

- 7
- 8 *Co-first authors
- 9 [‡]Co-senior authors
- 10
- ^[a] Transplant AI initiative, Ajmera Transplant Centre, University Health Network, University of Toronto, ON, Canada
- ^[b] Toronto General Hospital Research Institute, University Health Network, Toronto, ON,
 Canada
- 15 ^[c] Department of Surgery, University of California Irvine, Orange, California, USA
- 16 ^[d] McGill University Health Center, Montreal, Quebec, Canada
- 17 ^[e] Department of Surgery, University of Toronto, Toronto, ON, Canada
- 18 ^[f] Division of Gastroenterology & Hepatology, Department of Medicine, University of Toronto,
- 19 Toronto, ON, Canada
- 20 ^[g] Department of Computer Science, University of Toronto, Toronto, ON, Canada
- 21 ^[h] Vector Institute, Toronto, ON, Canada
- 22 ^[i] Princess Margaret Cancer Center, University Health Network, Toronto, ON, Canada
- 23 ^[]] Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada
- 24 ^[k] Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
- 25 ^[1] Peter Munk Cardiac Center and Ted Rogers Centre for Heart Research, University Health
- 26 Network, Toronto, ON, Canada
- 27
- 28
- 29

30 **Corresponding author:**

- 31 Mamatha Bhat, MD PhD
- 32 Department of Medicine, Division of Gastroenterology & Hepatology
- 33 University of Toronto
- Partnerships & Engagement Lead, Temerty Centre for AI in Research & Education in Medicine
- 35 (T-CAIREM)
- 36 Faculty Affiliate, Vector Institute for Artificial Intelligence
- 37 Email: Mamatha.Bhat@uhn.ca
- 38
- 39
- 40

41

42 Abstract

43 Many clinical questions in medicine cannot be answered through randomized controlled trials 44 (RCTs) due to ethical or feasibility constraints. In such cases, observational data is often the 45 only available resource for evaluating treatment effects. To address this challenge, we have 46 developed Decision Path Similarity Matching (DPSM), a novel machine learning (ML)-based 47 algorithm that simulates RCT-like conditions to debias observational data. In this study, we 48 apply DPSM to the clinical question of living donor liver transplantation (LDLT) versus deceased 49 donor liver transplantation (DDLT), helping to identify which patients benefit most from LDLT. 50 DPSM leverages decision paths from a Random Forest classifier to perform accurate, one-to-51 one matching between LDLT and DDLT recipients, minimizing confounding while retaining 52 interpretability. Using data from the Scientific Registry of Transplant Recipients (SRTR), 53 including 4,473 LDLT and 68,108 DDLT patients transplanted between 2002 and 2023, we 54 trained independent Random Survival Forest (RSF) models on the matched cohorts to predict 55 post-transplant survival. DPSM successfully reduced confounding associations between the two 56 groups as shown by a decrease in area under the receiver operating characteristic (AUROC) 57 from 0.82 to 0.51. Subsequently, RSF (C-index_{ldt}=0.67, C-index_{ddt}=0.74) outperformed the 58 traditional Cox model (C-index_{Idlt}=0.57, C-index_{ddlt}=0.65). The predicted 10-year mean survival 59 gain was 10.3% (SD = 5.7%). In conclusion, DPSM provides an effective approach for creating 60 RCT-like comparability from observational data, enabling personalized survival predictions. By 61 leveraging real-world data where RCTs are impractical, this method offers clinicians a tool for 62 transitioning from population-level evidence to more nuanced, personalization. 63 64

- 65
- 66
- 67
- 68
- 69
- 70
- 71

72

73 **1. Main**

- 74 Many clinical questions in medicine cannot be addressed through randomized controlled trials¹
- 75 (RCTs) due to ethical, logistical, or practical challenges. In liver transplantation (LT), for
- reample, it is not feasible to randomize patients between living donor liver transplantation
- 77 (LDLT) and deceased donor liver transplantation (DDLT) because of the ethical implications of
- assigning healthy donors and the urgency for life-saving transplants²⁻⁴. As a result, we often rely
- on observational data to assess the relative benefits of LDLT and DDLT.
- 80 Clinically, LDLT offers significant advantages over DDLT, such as reduced waitlist times^{5–8},
- 81 improved graft quality^{5,9}, and lower rejection rates¹⁰. Despite these benefits, LDLT remains
- 82 underutilized, representing only 5% of all LT cases in the United States⁶. Previous studies^{5,10,11}
- 83 have shown general survival benefits of LDLT compared to DDLT, but they lack sufficient
- 84 adjustment for confounding factors, making it difficult for clinicians to determine which individual
- 85 patients would benefit most from LDLT.
- 86 RCTs are considered the gold standard for assessing intervention effects, but as mentioned,
- 87 they are not feasible in the LDLT versus DDLT context. This has led to the development of
- 88 advanced statistical and machine learning methods that can simulate RCT-like conditions using
- 89 observational data. Propensity Score Matching (PSM)^{12,13} is one such method, but it has
- 90 limitations. By reducing complex, multi-dimensional covariate space into a single probability
- 91 score, PSM can fail to balance key variables and interactions, leading to residual confounding
- 92 and imprecise graft-type effect estimates^{14–16}.
- 93 In response to these limitations, we introduce Decision Path Similarity Matching (DPSM), a
- 94 novel machine learning-based algorithm designed to improve matching by leveraging the
- 95 decision paths from Random Forest models. Unlike PSM, our method matches patients based
- 96 on entire decision paths rather than a single probability score. This richer representation
- 97 captures complex, non-linear relationships between covariates, enabling more precise matching
- 98 and minimizing confounding. DPSM also allows for explainability by providing per-matched-pair
- 99 visualization of the key variables driving the decision-making process.
- After applying DPSM to match LDLT and DDLT patients, we utilize a time-to-event machine
 learning framework, specifically Random Survival Forest (RSF) models, to predict long-term

- 102 survival outcomes. To the best of our knowledge, no existing method offers individualized
- 103 survival benefit predictions for LDLT versus DDLT based on patient-specific variables, making
- 104 this work a significant advancement in the field.
- 105
- 106 **2. Results**
- 107 2.1. Patient characteristics
- 108 A total of 72,581 LT recipients were included in the study. DDLTs constituted 93.8% ($n_{ddlt} =$
- 109 68,108), while LDLTs comprised a much lesser percentage at 6.2%, ($n_{ldlt} = 4,473$).
- 110 Demographic and clinical study variables for both groups are reported in Table 1. DDLT patients
- 111 had higher rates of post-transplant mortality (29.7%) as compared to LDLT (22.3%).

Characteristics	LDLT population $(n = 4, 473)$	DDLT population $(n = 68, 108)$	<i>p</i> -value
Age (years)	51.5 (12.8)	52.9 (10.4)	<0.001
Sex Female (%) Male (%)	48.3 51.7	35.6 64.4	<0.001
Height (cm)	169.9 (10.3)	172.3 (10.3)	<0.001
Weight (kg)	78.8 (17.7)	87.2 (20.3)	<0.001
BMI	27.2 (5.2)	29.3 (5.9)	<0.001
Blood type (%) A AB B O	43.3 1.9 9.8 45.0	36.7 5.4 13.5 44.4	<0.001 <0.001 <0.001 0.375
MELD	14.0 (4.5)	22.4 (8.7)	0.000
Primary etiology (%) Alcoholic Cirrhosis Autoimmune Hepatitis Cryptogenic Cirrhosis HBV Cirrhosis HCV Cirrhosis Metabolic Liver Disease MASH PSC PBC Other	15.1 4.6 6.9 1.0 15.8 2.0 16.9 19.0 8.9 8.0	29.4 3.5 6.6 1.7 22.1 2.2 15.3 5.2 3.7 7.9	<0.001 <0.001 0.378 <0.001 <0.001 0.374 0.007 0.956 <0.001 <0.001

112

 Table 1. Clinicodemographic characteristics of LDLT, DDLT recipients.

113

114 **2.2. LDLT-DDLT matching**

115 In our study, where the goal is to estimate the survival benefit associated with receiving one 116 type of intervention (LDLT) over another (DDLT), it becomes necessary to minimize 117 confounding associations to ensure that our findings are not subject to bias. To this end, we 118 developed the DPSM matching algorithm (details in Sec. 4.4) that performs optimal one-to-one 119 matching between LDLT and DDLT patients using all study variables listed in Sec. 4.2 (Fig. 1a). 120 Unlike propensity score matching (PSM), which matches patients based on an output probability 121 scalar, DPSM leverages and scores entire decision paths produced by a Random Forest model. 122 This approach not only enhances the accuracy of the matching process but also increases the 123 explainability of the method, providing a more transparent and interpretable framework for

- 124 understanding factors influencing the matching.
- 125

126 First, we evaluated the effectiveness of our matching technique. Fig. 1b compares 1-D, 2-D pre-127 and post-match distributions for 2 key variables: age and MELD score across LDLT, DDLT 128 patients. We observe a high degree of overlap for the matched populations, confirming the 129 success of our method. Originally, DDLT patients had a relatively higher MELD score (22.4 \pm 130 8.7) than those that received an LDLT (14.0 \pm 4.5). High MELD (>33) patients, generally much 131 sicker, are unable to be matched as they do not possess an LDLT counterpart. All other 132 variables used in the study were also found to exhibit good matching (Fig. S2). Additionally, we 133 sought to understand how matching impacts survival times of LDLT and DDLT patients. Kaplan-134 Meier analysis estimated LDLT and DDLT median survival times in the original dataset to be 135 219 and 184 months respectively (Fig. 1c). After matching using our DPSM technique, we 136 observed a slight decrease in median survival times for the two groups ($t_{surv. ldlt} = 215$ months, 137 t_{surv. ddlt} = 176 months) (Fig. 1d). For completeness, survival times after PSM matching were also 138 computed ($t_{surv, ldlt} = 219$ months, $t_{surv, ddlt} = 192$ months) (Fig. 1e).

139

140 Next, we quantitatively evaluated the efficacy of our DPSM method by computing the AUROC of 141 a Random Forest classifier trained on the pre- and post-matched datasets (Fig. 1f). The mean 142 AUROC performance dropped significantly from 0.83 on the original dataset to 0.51 after 143 matching, indicating that the model found it challenging to accurately classify patients as LDLT 144 or DDLT, thus demonstrating the success of our matching process in reducing systematic 145 differences between the two groups. Notably, post-match AUROC for DPSM (0.509 \pm 0.018) was lower than that achieved using traditional PSM (0.589 ± 0.007), suggesting that our method 146 147 performed better in achieving balanced and comparable groups. This enables establishment of 148 a clearer causal relationship between graft type and survival outcomes.



Fig. 1. LDLT-DDLT Matching.

(a) Workflow of our DPSM algorithm; (b) 1-D/2-D distributions (histogram) for recipient age and MELD score variables pre- and post-matching; (c) observed LDLT, DDLT survival in original dataset (pre-match); (d) observed LDLT, DDLT survival post-DPSM-matching; (e) observed LDLT, DDLT survival post-PSM-matching; (f) post-match AUROCs achieved by our DPSM and traditional PSM methods for the graft-type prediction task. The ideal case is AUROC=0.5, which corresponds to an actual RCT. Error bars indicate standard deviations across 10 random samplings.

- 149
- 150 A key advantage of our DPSM method is its ability to provide explainable matching, enhancing
- the transparency of the model's decision-making process. To illustrate this, we show the 10
- 152 most frequently occurring patient variables in the decision paths across all trees of the Random
- 153 Forest. This type of interpretability is essential because it transforms a complex, "black-box"
- setup into something that can be understood by researchers and clinicians. Fig. 2 shows these
- 155 explanations for three randomly selected LDLT-matched DDLT patient pairs, where we observe

- that MELD score, waitlist time, weight and BMI are the top variables that influence the model
- deciding whether a patient received an LDLT or DDLT. Other patient characteristics such as
- age, sex and height were also found to be important predictors. Among etiologies, Alcoholic
- 159 Cirrhosis, HCV Cirrhosis and PSC were deemed important by the Random Forest model to
- 160 make graft-type predictions.



Fig. 2. Frequently occurring patient characteristics across forest-level decision paths.

For a given LDLT-matched DDLT patient pair, we show the 10 most frequently occurring variables across decision paths across all Trees of the Random Forest. A high degree of overlap indicates similarity between the two patients (differing by graft-type) in terms of how the forest makes decisions. This is illustrated for 3 randomly chosen patient pairs.

161

162 **2.3. Evaluation of survival model**

Building on the matched LDLT and DDLT cohorts generated by DPSM, we trained and
evaluated survival models to predict patient survival outcome. Methodological details are
provided in Sec. 4.5. For this task, we compared the performance of two popular time-to-event
models, Random Survival Forest (RSF) and Cox Proportional Hazards (CPH). Two independent
models were trained on the LDLT and matched DDLT populations.

168

169 In general, RSF ($C - index_{ldlt} = 0.673$, $C - index_{ddlt} = 0.740$) performed better than CPH ($C - index_{ldlt} = 0.673$) performed better than CPH ($C - index_{ldlt} = 0.673$).

170 $index_{ldlt} = 0.572, C - index_{ddlt} = 0.652$) on the C-index and was therefore selected as the

171 model of choice (Fig 3b). The improved performance may be attributed to the former's ability to

- 172 model non-linear data patterns without making explicit assumptions about underlying
- distributions. The average Brier score did not exceed 0.14. Additionally, we performed SHAP
- analysis to understand feature contributions to our outcome of interest, i.e., post-transplant
- 175 mortality (Fig. 3c, d). Recipient age emerged as the strongest predictor of mortality with older
- 176 patients at much greater risk. Other important factors were weight, BMI, MELD, height and
- 177 blood type A. In terms of the primary indication for transplant, PSC, MASH, Alcoholic Cirrhosis
- and HCV Cirrhosis were all found to be important risk factors. In light of these findings, it
- 179 becomes important to point out that variables such as age, MELD score, weight and BMI have

- 180 been identified as key confounders. This is because these variables impact both, graft-type
- 181 assignment (Fig. 2) as well as survival outcome.



Fig. 3. Performance evaluation and SHAP.

(a) Model training and evaluation methodology: LDLT, DDLT cohorts are passed into the DPSM matching algorithm using all selected variables to account for confounding. Matched cohorts with waitlist time excluded are split into train and test sets. 2 graft-specific models are trained independently on the training samples, using a k-fold (k=5) cross-validation strategy and the best model across various hyperparameter settings is selected based on minimum Brier score. C-index is computed on the validation set and the best model is saved for further evaluation on the held-out test set; (b) RSF model C-index computed on the test set. Random Survival Forest (RSF) performance is compared with Cox proportional hazards (CPH) model, used as a baseline. Average Brier score varied from 0.10-0.14; top 10 features as predicted by SHAP on test set patients; (c) RSF-LDLT model applied to LDLT patients; (d) RSF-DDLT model applied to matched DDLT patients.

182

183 2.4. Estimation of LDLT benefit

- 184 A major strength of our ML-based technique is its ability to personalize survival prediction by
- incorporating individual patient variables into the modeling process. The emphasis in this
- section is on estimating the benefit in receiving an LDLT over a DDLT for an individual patient.
- 187 To achieve this, we applied the trained RSF-LDLT and RSF-DDLT models to the LDLT and their
- 188 matched DDLT counterparts, respectively. By contrasting the survival predictions generated by
- these models, we can estimate the personalized benefit of LDLT for each patient.



Fig. 4. LDLT versus DDLT survival for individual patient.

(a) Estimation of LDLT survival benefit: LDLT, DDLT survival models are applied independently to obtain the predicted survival functions $p_{s, ldlt}(t)$ and $p_{s, ddlt}(t)$ for LDLT and matched DDLT recipients (test), respectively. At a desired evaluation time-point, fractional LDLT survival benefit is defined as the probability difference between LDLT and DDLT survival normalized by DDLT survival; (b) LDLT benefit (%) at 1-, 3-, 5- and 10-years post-transplant for a patient diagnosed with PSC. Blue and red curves show survival functions of the LDLT and matched DDLT patient predicted by the respective models. Individual SHAP explanations (c) as well as corresponding patient characteristics (d) are also shown.

- 190
- 191 Fig. 4 shows individual examples for two etiologies of interest: for the patient diagnosed with
- 192 Primary Sclerosing Cholangitis (PSC), our model predicts a 10-year survival gain of 16.8 % (Fig.
- 4b). To further understand the factors driving this predicted benefit, we conducted a patient-
- 194 specific differential SHAP analysis (Fig. 4c), which identifies the key features contributing to
- 195 survival gain. Variables highlighted in blue are associated with increased survival gain, while
- those in red indicate increased risk. The top variables that strongly influenced benefit were
- 197 MELD, height, PSC and BMI. Original patient variables are also shown (Fig. 4d).
- 198
- 199 Next, we compute the population-level predicted LDLT benefit by considering the matched
- 200 patient groups. This is done on the held-out test set of patients, untouched during the model
- training process (Fig. 5a). Based on variables at the time of listing, our ML model predicts a

- 202 mean long-term (10-year) benefit of 10.3%. For validation, we also performed standard Kaplan-
- 203 Meier analysis on the same set of patients to evaluate observed LDLT versus DDLT survival
- 204 differences (Fig. 5b).



Fig. 5. LDLT survival benefit.

(a) 1, 3, 5 and 10-year fractional survival benefit of receiving LDLT over DDLT ($n_{test} = 401$) for LDLT recipients. If *t* does not exist for either of the LDLT, DDLT models, we perform interpolation, so that % benefit can be computed appropriately; (b) Kaplan-Meier estimator applied on the test set confirms LDLT survival benefit at the population-level. Survival times are cut-off at 120 months (10-years).

205

206 2.5. Etiology-specific benefit

- 207 Finally, we evaluated the predicted survival benefit of LDLT over DDLT across six different
- 208 etiologies (primary diagnoses) within the matched cohort, namely Autoimmune Hepatitis (AH),
- 209 PBC, PSC, HCV Cirrhosis (HCV), MASH, and Alcoholic Cirrhosis (AC). By analyzing the
- 210 survival outcomes for specific diseases, we aimed to identify which etiologies were associated
- 211 with the highest LDLT benefit.



Fig. 6. Etiology-specific benefit.

(a) Bar chart shows 10-year (long-term) post-transplant LDLT benefit (%) for each of the 6 distinct etiologies: Alcoholic Cirrhosis, Autoimmune Hepatitis, HCV Cirrhosis, MASH, PBC and PSC. Results are computed on the held-out test set, these patients are untouched during RSF model training; (b) observed survival (Kaplan-Meier) for all 6 etiologies to evaluate matched LDLT (blue) vs DDLT (red) survival differences. Survival data is cut-off at 10 years.

- 212
- 213 Using our ML-guided approach, we computed the differential survival gain of LDLT for each
- 214 patient and then aggregated these results based on their primary diagnosis (Fig. 6a). The
- analysis revealed that certain etiologies exhibited a significantly higher survival benefit when
- transplanted with LDLT compared to DDLT. Patients diagnosed with PSC (12.4 ± 5.3 %) and
- HCV (12.1 ± 5.7 %) showed substantial long-term survival advantages with LDLT, over a 10-
- 218 year period. For comparison with ground truth, we also evaluated observed survival differences
- between the two groups (Fig. 6b). These findings suggest that LDLT may be particularly
- advantageous for patients with these conditions, potentially influencing clinical decision-
- 221 making.
- 222
- 223 **3.** Discussion

224 The challenge of determining which patients would benefit most from receiving a living donor 225 liver transplant (LDLT) versus a deceased donor liver transplant (DDLT) is compounded by the 226 impracticality of conducting randomized controlled trials (RCTs). To address this, we create a 227 novel approach which we call Decision Path Similarity Matching (DPSM) algorithm, that 228 combines advanced matching and machine learning (ML) techniques to emulate the balanced 229 conditions of an RCT using observational data to personalize survival predictions. By effectively 230 minimizing confounding factors, DPSM enables causal-type estimation of the effect of graft-type 231 on post-transplant survival.

232

233 **3.1. DPSM: a novel, multivariate method for one-to-one matching**

234 Our innovative algorithm represents a significant advancement in the field of observational study

235 design, particularly in contexts where conducting randomized controlled trials (RCTs) is

236 impractical or impossible. Unlike traditional Propensity Score Matching (PSM), which

237 compresses complex patient data into a single propensity score, DPSM leverages the full

238 decision paths generated by a Random Forest classifier to perform one-to-one matching

between LDLT and DDLT patients. This approach allows DPSM to retain the multidimensional

complexity of patient data, resulting in more nuanced and accurate matching that closely mimicsthe balance achieved in RCTs.

242

The key strength of DPSM is its ability to minimize confounder bias, thereby producing more balanced cohorts than traditional PSM. Our study demonstrated that DPSM significantly decreased the AUROC for graft-type prediction after matching, a clear indication that DPSM more effectively mitigates covariate differences between the LDLT and DDLT groups. This enhanced performance is crucial in creating a robust foundation for subsequent survival analysis, ensuring that any observed differences in outcomes are attributable to graft-type

- 249 differences.
- 250

Additionally, by utilizing decision paths instead of a single scalar score, DPSM allows clinicians and researchers to understand the prominent variables involved in the decision-making process leading up to the matching. These insights are particularly valuable in clinical settings, where understanding the rationale behind matching decisions can foster greater confidence in the study's findings and support more informed clinical decision-making. The ability to visualize and interpret the decision-making process also aligns DPSM more closely with the principles of RCTs, where the reasoning behind patient assignment is clear and systematic.

258

In summary, DPSM is a powerful technique, enabling researchers to simulate the conditions of an RCT more effectively in observational studies. Its superior matching performance and transparency make it a valuable tool not only for advancing research in liver transplantation but also for broader applications where the target questions are causal in nature. As the field of clinical research increasingly turns to observational data in the absence of feasible RCTs, methods like DPSM will play a critical role in ensuring that the insights drawn from these studies are both accurate and actionable.

266

267 **3.2. ML framework for personalized survival predictions**

268 Applying our RSF model on a test set of patients, we report a mean predicted LDLT survival 269 gain of 2.7%, 6.6%, 7.1% and 10.3% at 1-, 3-, 5- and 10-years post-transplant respectively. It is 270 worth placing this in the context of prior evidence pertaining to LDLT versus DDLT survival. 271 Barbetta et. al.¹⁰ also analyzed SRTR data and found a mortality risk reduction of 17%, 15% 272 and 13% at 1-, 3- and 5-year post-transplant for LDLT recipients. Higher estimated benefit in the 273 latter is suspected to be a consequence of the lack of matching in their analysis. In fact, another 274 study¹¹ around the same time that analyzed Canadian transplant recipients found that graft-type 275 differences got washed away upon adjustment for donor as well as recipient characteristics. 276

277 In our study, where we predict individual LDLT benefit using patient-specific variables at the 278 time of listing, we find significant heterogeneity across all patients that we evaluated our method 279 on, underscoring the importance of personalization. The ability to predict individualized survival 280 outcomes allows clinicians to move beyond a 'one-size-fits-all' approach, enabling more tailored 281 decisions that align with the specific characteristics and needs of each patient. This not only 282 optimizes transplant outcomes but also enhances patient counseling, as clinicians can provide 283 more accurate, data-driven information to patients and their families when discussing treatment 284 options.

285

Finally, our etiology-specific analysis underscores the importance of individualized treatment planning, as the survival benefit of LDLT can vary significantly depending on the underlying liver disease. These insights could guide clinicians in making more informed decisions about transplant strategies, particularly for patients with specific diagnoses where LDLT offers the most substantial benefit. Among all etiologies tested, our ML tool predicted the highest benefit for patients diagnosed with PSC (12.4 ± 5.3 %). These patients often experience slow

292 progression of the disease, but when complications such as cholangitis arise, timely

transplantation becomes critical. LDLT, with its shorter wait times, offers a significant survival

- advantage in such urgent cases. Our result is backed by a recent study by Sierra *et. al.*¹⁷, which
- also reported a long-term (10-year) survival advantage for PSC patients who received an LDLT
- 296 (81.9 %) over a DDLT (72.7 %).
- 297

Integrating these personalized predictions into clinical workflows could significantly improve
 decision-making processes, ensuring that patients are referred for LDLT especially when the
 survival benefit is significant. As the field of liver transplantation progresses towards precision-

301 based approaches, tools like these will become essential in guiding downstream clinical

decisions and potentially improving overall patient care.

303

304 **3.3. Study strengths and limitations**

305 This study has several notable strengths that enhance its contribution to the field of liver 306 transplantation. First, the development and application of the Decision Path Similarity Matching 307 (DPSM) algorithm represents a significant advancement in observational study design, allowing 308 us to create well-matched cohorts that closely mimic the conditions of an RCT. This is evident in 309 the substantial reduction in systematic differences between the LDLT and DDLT cohorts, as 310 evidenced by the drop in AUROC from 0.83 (pre-matching) to 0.51 (post-matching), which 311 shows that our algorithm effectively removed confounding associations among variables. By 312 reducing bias and aligning survival outcomes across groups, DPSM enables a more accurate 313 comparison of LDLT and DDLT outcomes, which is crucial in the absence of feasible RCTs. 314 Additionally, the integration of Random Survival Forest (RSF) models to provide personalized 315 survival predictions adds a valuable dimension to clinical decision-making, offering tailored 316 insights that can optimize patient care.

317

318 Our study also has important limitations. The retrospective nature of the analysis, relying on 319 data from the SRTR, may introduce biases inherent in observational studies. It is important to 320 note that DPSM is able to mitigate these confounding biases, as long as they are observable, 321 i.e., captured within our dataset. Another limitation is the reliance on clinico-demographic 322 variables available at the time of listing, which, although comprehensive, may not capture all 323 factors influencing transplant outcomes. Incorporating additional variables, such as genetic 324 markers or more detailed comorbidity data, could further refine the predictive models and 325 enhance the precision of survival estimates.

326

327	We also acknowledge the absence of external validation as a limitation of this study. This was
328	primarily due to the lack of access to sufficiently large datasets outside the SRTR. DPSM
329	performs optimally with larger sample sizes, especially the DDLT pool, as these allow for more
330	reliable transformation of observational data into RCT-like conditions. Smaller datasets may not
331	provide the robustness needed for effective matching, underscoring the importance of future
332	research focused on validating these findings in different cohorts and clinical environments.
333	Finally, while the RSF model demonstrated good performance in this study, further validation in
334	prospective studies and across different cohorts is necessary to confirm its broader applicability.
335	
336	In conclusion, this study introduces a novel Decision Path Similarity Matching (DPSM)
337	methodology, which represents a significant advancement in creating RCT-like comparability
338	from observational data and debiasing transplant outcomes. DPSM offers a more transparent
339	and explainable approach to matching patients compared to traditional methods, allowing for
340	personalized predictions of survival benefit in living donor liver transplantation. While further
341	research and external validation are required to enhance its robustness and generalizability, the
342	innovations presented here mark an important step toward more individualized, data-driven
343	decision-making in liver transplantation.

344

345 **4. Methods**

346 4.1. Study Design

We conducted a retrospective, cross-sectional study from the SRTR database. The SRTR
includes data of all organ donors, as well as waitlisted and transplanted recipients in the United
States submitted by the Organ Procurement and Transplantation Network (OPTN). This study
was approved by the Research Ethics Board at the University Health Network.

351

Adult (≥18-years-old) LT patients, listed between 28th February 2002 and 23rd May 2023, were included in the analysis. Study exclusion criteria is clearly defined in Fig. S1. Patients with reported MELD scores greater than 40 were excluded. These patients (<5% of the entire population) are generally very sick and highly prone to pre-operative mortality, including them would make it challenging to clearly delineate the effect of transplant type on post-transplant survival. Recipients with previous or multi-organ transplants were excluded as were those

diagnosed with HIV, acute liver failure (ALF) and HCC. Patients who received exception pointswere also removed.

360

361 **4.2. Variables and Outcomes**

Clinico-demographic patient variables: age, sex, blood group, BMI, height, weight, MELD score, primary diagnosis (indication for transplant) and time on the waitlist were collected at the time of listing. For variable comparison between the LDLT, DDLT patient cohorts, an alpha level of <0.05 was selected as the significance threshold. Post-transplant, mortality (all-cause) was the outcome or event of interest and event times were defined from the time of transplant to either the time of death or censored at the date of last follow-up.

368

369 4.3. Data Preparation and Preprocessing

Covariates with greater than 20% missingness were excluded from the analysis. For continuous
 variables with missing values, mean imputation was performed. Categorical variables were one hot encoded (OHE). Subsequently, we ended up with 21, unit normalized input features to the
 ML model.

374

375 4.4. Matching

376 We designed and implemented a new method, Decision Path Similarity Matching (DPSM) to 377 account for confounding bias, ensuring that predicted survival differences would be 378 predominantly attributed to graft-type. The key feature of DPSM being that it uses the "similarity" 379 or closeness between decision paths, which provides a richer feature encoding as opposed to 380 matching based on output probabilities alone in the case of PSM. The constituent steps of our 381 algorithm are shown in Fig. 1a along with the pseudocode below (Fig. 7) - (1) first, the original 382 LDLT-DDLT dataset is randomly split into train (70%) and test (30%) sets. A Random Forest 383 (RF) classifier is trained on the training set to predict transplant type using all input variables 384 previously listed in Sec. 4.2. RF was selected due to its ability to capture non-linear 385 relationships among variables and handle imbalanced data, crucial in the LDLT versus DDLT context. (2) The best model is selected across a hyperparameter search ($n_{estimators} =$ 386 387 50, 100, 200, 300, 500, 1000, $min_{samples,leaf} = 500$) using k(=5)-fold cross-validation (cv) on the

train set and performance is evaluated on the test set using the area under the receiver operator

- 389 characteristic (AUROC) curve. (3) From the trained model, we extract decision paths for
- individual patients in the held-out test set, averaged across all the Trees in the Forest. This is an

- n-dimensional binary vector [1, 0, 1, 0, ..], where "n" is the total number of decision nodes
- (features) per tree. A node is "1" if it applies to a particular patient and "0" otherwise. (4)
- Hamming distance (d_H) is then computed for every pair of (LDLT, DDLT) decision paths. To
- remove "poor" matches or outliers, patients whose pairwise d_H exceeds a selected threshold
- 395 (th) are removed. The optimal threshold was determined as that which minimized
- $|AUROC_{post-match} 0.5|$, at an acceptable patient dropout rate (Table S1). We selected th =
- 397 0.45. (5) The filtered distance matrix is used to perform one-to-one matching using the "Munkres
- 398 Assignment" procedure¹⁸. This is an "optimal" algorithm that matches by minimizing the total
- Hamming distance across all LDLT-DDLT patient pairs. After this step, we repeat step (2) to
- 400 calculate the AUROC for the matched dataset using a k(=5)-fold cv strategy. The same set of
- 401 hyperparameters are used. Finally, match effectiveness is quantified as the difference between
- 402 pre- and post-match AUROCs.



Fig. 7. DPSM: pseudocode

403 404

405 **4.5. Model Training and Validation**

The matched sub-populations ($n_{ldlt} = n_{ddlt} = 1,337$) were first split into train (70%) and test (30%) sets ($n_{train} = 936$, $n_{test} = 401$). For the time-to-event survival prediction, two Random Survival Forest (RSF) models were trained independently on the matched LDLT-DDLT cohorts, respectively. Hyperparameter tuning was performed on the train dataset using k (=5)-fold cross validation and the model that produced minimum Brier score was selected as the best one. For validation, both C-index and Brier score, averaged across 5 evaluation time points: 0.5, 1, 3, 5 and 10 years were computed on the held-out test set. 413 During hyperparameter tuning, it is common to use C-index as the evaluation metric for time-to-

- 414 event models. While this is useful in understanding relative risk ranking, it is not informative
- 415 about the accuracy and calibration of the predicted survival predictions. We instead utilize the
- 416 Brier score, defined as follows: $BS = (1/N) \sum_{i=1}^{N} (gt_i p_i)^2$, where N is the sample size, gt_i and
- 417 p_i are the actual and predicted event probabilities for observation *i*. This metric quantifies the
- 418 error rate between prediction and ground truth, serving as an ideal choice for calibrating survival
- 419 models. Subsequently, the optimal hyperparameters selected are those that minimize the time-
- 420 averaged Brier score.
- 421

422 **4.6. Estimation of LDLT Survival Benefit**

- 423 For a given LDLT and matched DDLT patient, the corresponding trained models (RSF-LDLT,
- 424 RSF-DDLT) are applied to obtain the respective predicted survival functions $S_{ldlt}(t)$ and
- 425 $S_{ddlt}(t)$. RSF models produce unique event times according to the data they were trained on.
- 426 To ensure that both LDLT and DDLT models predict definitive survival for a given evaluation
- 427 time point t_i , we interpolate predicted survival probabilities across all time. Finally, differential
- 428 LDLT benefit is evaluated as $(S_{ldlt}(t) S_{matched \ ddlt}(t))/S_{matched \ ddlt}(t)$.
- 429

430 **5. Code availability**

- 431 The source code for this work is available on GitHub
- 432 (<u>https://github.com/Anivader/LDLT_survival_benefit_ML_tool</u>). All analysis was performed using
 433 Python.
- 434

435 **6. References**

- 436 1. Spieth, P. M. *et al.* Randomized controlled trials a matter of design. *Neuropsychiatr.*
- 437 *Dis. Treat.* **12**, 1341–1349 (2016).
- Schiano, T. D., Kim-Schluger, L., Gondolesi, G. & Miller, C. M. Adult living donor liver
 transplantation: The hepatologist's perspective. *Hepatology* 33, 3–9 (2001).
- Brown, J., Sorrell, J. H., McClaren, J. & Creswell, J. W. Waiting for a Liver Transplant. *Qual. Health Res.* 16, 119–136 (2006).
- 442 4. Larson, A. M. & Curtis, J. R. Integrating Palliative Care for Liver Transplant
- 443 Candidates"Too Well for Transplant, Too Sick for Life". *JAMA* **295**, 2168–2176 (2006).

444 5. Humar, A. et al. Adult Living Donor Versus Deceased Donor Liver Transplant (LDLT 445 Versus DDLT) at a Single Center: Time to Change Our Paradigm for Liver Transplant. Ann. 446 Surg. 270, 444 (2019). 447 Ivanics, T. et al. Low utilization of adult-to-adult LDLT in Western countries despite 6. 448 excellent outcomes: International multicenter analysis of the US, the UK, and Canada. J. 449 Hepatol. 77, 1607–1618 (2022). 450 7. Tran, L. & Humar, A. Expanding living donor liver transplantation in the Western world: 451 changing the paradigm. *Dig. Med. Res.* **3**, (2020). 452 Karnam, R. S. et al. Sex Disparity in Liver Transplant and Access to Living Donation. 8. 453 JAMA Surg. 156, 1010–1017 (2021). 454 9. Lee, S.-G. A Complete Treatment of Adult Living Donor Liver Transplantation: A Review 455 of Surgical Technique and Current Challenges to Expand Indication of Patients. Am. J. 456 Transplant. 15, 17–38 (2015). 457 10. Barbetta, A. et al. Meta-analysis and meta-regression of outcomes for adult living donor 458 liver transplantation versus deceased donor liver transplantation. Am. J. Transplant. Off. J. 459 Am. Soc. Transplant. Am. Soc. Transpl. Surg. 21, 2399-2412 (2021). 460 11. Goto, T. et al. Superior Long-Term Outcomes of Adult Living Donor Liver 461 Transplantation: A Cumulative Single-Center Cohort Study With 20 Years of Follow-Up. Liver 462 Transpl. 28, 834-842 (2022). 463 12. Benedetto, U., Head, S. J., Angelini, G. D. & Blackstone, E. H. Statistical primer: 464 propensity score matching and its alternatives[†]. Eur. J. Cardiothorac. Surg. 53, 1112–1117 465 (2018). 466 13. Abadie, A. & Imbens, G. W. Matching on the Estimated Propensity Score. Econometrica 467 **84**, 781–807 (2016). 468 14. King, G. & Nielsen, R. Why Propensity Scores Should Not Be Used for Matching. Polit. 469 Anal. 27, 435–454 (2019). 470 Nguyen, T.-L. et al. Double-adjustment in propensity score matching analysis: choosing 15. 471 a threshold for considering residual imbalance. BMC Med. Res. Methodol. 17, 78 (2017). 472 16. Rubin, D. B. & Thomas, N. Combining Propensity Score Matching with Additional 473 Adjustments for Prognostic Covariates. J. Am. Stat. Assoc. 95, 573–585 (2000). 474 17. Sierra, L. et al. Living-Donor Liver Transplant and Improved Post-Transplant Survival in 475 Patients with Primary Sclerosing Cholangitis. J. Clin. Med. 12, 2807 (2023). 476 18. Munkres, J. Algorithms for the Assignment and Transportation Problems. J. Soc. Ind. 477 Appl. Math. 5, 32–38 (1957).

478

479 **7.** Acknowledgements

- 480 Mamatha Bhat acknowledges support from the Toronto General and Western Hospital
- 481 Foundation, Canadian Institutes for Health Research and Canadian Donation and Transplant
- 482 Research Program. Chris McIntosh holds the Chair in Medical Imaging at the Joint Department
- 483 of Medical Imaging at the University Health Network, and the Department of Medical Imaging at
- 484 the University of Toronto. Michael Brudno holds a CIFAR AI Chair.
- 485

486 8. Author contributions

- 487 A.G., C.M., M. Bhat. and Y.S. conceptualized the study. C.M. supervised the experimental
- design, A.G. developed the computational analysis pipelines and generated all the data. Y.S.
- helped with the data pre-processing script. B.J.H. and X.Z. helped with clinical interpretability.
- 490 A.G. wrote the manuscript and C.M., B.J.H., M. Bhat provided feedback and M. Brudno
- 491 reviewed the manuscript. C.M. and M. Bhat. supervised the study.

492

493 **9. Ethics declarations**

494 The authors declare no competing interests.